Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Keros Therapeutics Inc (NASDAQ: KROS) closed at $12.82 down -11.95% from its previous closing price of $14.56. In other words, the price has decreased by -$11.95 from its previous closing price. On the day, 2.31 million shares were traded. KROS stock price reached its highest trading level at $14.1 during the session, while it also had its lowest trading level at $12.3501.
Ratios:
For a deeper understanding of Keros Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on December 16, 2024, Reiterated its Outperform rating but revised its target price to $63 from $102 previously.
H.C. Wainwright reiterated its Buy rating for the stock on December 13, 2024, while the target price for the stock was revised from $100 to $47.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 589787904 and an Enterprise Value of 7906983. For the stock, the TTM Price-to-Sale (P/S) ratio is 798.93 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 12.146 whereas that against EBITDA is -0.039.
Stock Price History:
The Beta on a monthly basis for KROS is 1.44, which has changed by -0.72616136 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $13.96. The 50-Day Moving Average of the stock is -70.46%, while the 200-Day Moving Average is calculated to be -74.64%.
Shares Statistics:
For the past three months, KROS has traded an average of 931.59K shares per day and 947130 over the past ten days. A total of 39.26M shares are outstanding, with a floating share count of 32.86M. Insiders hold about 18.87% of the company’s shares, while institutions hold 83.72% stake in the company. Shares short for KROS as of 1734048000 were 3025140 with a Short Ratio of 4.63, compared to 1731628800 on 2224037. Therefore, it implies a Short% of Shares Outstanding of 3025140 and a Short% of Float of 10.17.
